WhiteLab Genomics
YC W22Paris, FR · Founded 2019 · 40 employees · 1 known investors
WhiteLab Genomics uses AI and computational methods to analyze biological data and accelerate genomic drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to reduce timelines and de-risk the development of genomic medicines.
AI & Machine LearningBiotechDeep TechHealthtechArtificial IntelligenceGene TherapyCell TherapyGenomicsin /whitelabgenomics/@whitelabg
Founders & leadership· Y Combinator alumni (W22)
Investors · 1
In the news
- Debiopharm Co-leads a Series A Round in Whitelab Genomics - Debiopharmdebiopharm.com · 2022
- WhiteLab Genomics raises $10M for AI-powered genomic therapies platformlabiotech.eu · 2022
- How WhiteLab Genomics is using AI to aid gene and cell therapy development • TechCrunchtechcrunch.com · 2022
- WhiteLab Genomics - 2025 Company Profile, Funding & Competitors - Tracxntracxn.com · 2022
- WhiteLab Genomics and the Accelerator for Technological Research in Genomic Therapies Announce Their Collaboration on Artificial Intelligence for the Bioproduction of Gene Therapiesbusinesswire.com · 2021
- WhiteLab Genomics raised $10 million Series A funding from Debiopharm Innovation Fund and Omnes Capital. | Nordic 9nordic9.com